{"FP": [{"generated": ["saline solution"], "gold": [], "text": "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)"}], "FN": [{"generated": [], "gold": ["trabectedin"], "text": "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event."}, {"generated": [], "gold": ["trabectedin"], "text": "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin."}, {"generated": [], "gold": ["ropinirole", "carbidopa-levodopa", "entacapone"], "text": "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8]."}, {"generated": [], "gold": ["ropinirole", "carbidopa-levodopa", "entacapone"], "text": "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8]."}, {"generated": [], "gold": ["ropinirole", "carbidopa-levodopa", "entacapone"], "text": "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8]."}, {"generated": [], "gold": ["carbidopa-levodopa"], "text": "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1)."}, {"generated": [], "gold": ["morphine"], "text": "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34]."}, {"generated": [], "gold": ["gliclazide"], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": [], "gold": ["gliclazide"], "text": "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide."}, {"generated": [], "gold": ["tolbutamide", "glipizide"], "text": "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively."}, {"generated": [], "gold": ["tolbutamide", "glipizide"], "text": "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively."}, {"generated": [], "gold": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"], "text": "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8]."}, {"generated": [], "gold": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"], "text": "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8]."}, {"generated": [], "gold": ["LVFX"], "text": "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX."}, {"generated": [], "gold": ["LVFX"], "text": "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices."}, {"generated": [], "gold": ["LVFX"], "text": "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue."}, {"generated": [], "gold": ["Penicillin-streptomycin"], "text": "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA)."}, {"generated": [], "gold": ["digoxin"], "text": "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates."}, {"generated": [], "gold": ["digoxin"], "text": "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006)."}, {"generated": [], "gold": ["hypoglycemic drugs", "hypocholesterolemic drugs", "thiazolidinediones (TZDs)", "atorvastatin", "sulfonylureas"], "text": "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin."}, {"generated": [], "gold": ["hypoglycemic drugs", "hypocholesterolemic drugs", "thiazolidinediones (TZDs)", "atorvastatin", "sulfonylureas"], "text": "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin."}, {"generated": [], "gold": ["hypoglycemic drugs", "hypocholesterolemic drugs", "thiazolidinediones (TZDs)", "atorvastatin", "sulfonylureas"], "text": "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin."}, {"generated": [], "gold": ["hypoglycemic drugs", "hypocholesterolemic drugs", "thiazolidinediones (TZDs)", "atorvastatin", "sulfonylureas"], "text": "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin."}, {"generated": [], "gold": ["hypoglycemic drugs", "hypocholesterolemic drugs", "thiazolidinediones (TZDs)", "atorvastatin", "sulfonylureas"], "text": "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin."}, {"generated": [], "gold": ["sulfaphenazole", "ketoconazole"], "text": "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor)."}, {"generated": [], "gold": ["sulfaphenazole", "ketoconazole"], "text": "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor)."}, {"generated": [], "gold": ["docetaxel"], "text": "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel."}, {"generated": [], "gold": ["docetaxel"], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": [], "gold": ["docetaxel"], "text": "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax)."}, {"generated": [], "gold": ["docetaxel"], "text": "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea)."}, {"generated": [], "gold": ["docetaxel"], "text": "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3."}, {"generated": [], "gold": ["midazolam"], "text": "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome."}, {"generated": [], "gold": ["midazolam"], "text": "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified."}, {"generated": [], "gold": ["docetaxel", "dexamethasone"], "text": "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel."}, {"generated": [], "gold": ["docetaxel", "dexamethasone"], "text": "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel."}, {"generated": [], "gold": ["zosuquidar", "docetaxel"], "text": "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients."}, {"generated": [], "gold": ["zosuquidar", "docetaxel"], "text": "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients."}, {"generated": [], "gold": ["digoxin"], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": [], "gold": ["digoxin"], "text": "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin."}, {"generated": [], "gold": ["digoxin"], "text": "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study."}, {"generated": [], "gold": ["methotrexate"], "text": "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group."}, {"generated": [], "gold": ["MTX"], "text": "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis."}, {"generated": [], "gold": ["MTX"], "text": "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies."}, {"generated": [], "gold": ["AC"], "text": "However, it is unknown whether there is an interaction between AC and DST."}, {"generated": [], "gold": ["AC"], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": [], "gold": ["AC"], "text": "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL."}, {"generated": [], "gold": ["digoxin"], "text": "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results."}, {"generated": [], "gold": ["digoxin"], "text": "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A."}, {"generated": [], "gold": ["digoxin"], "text": "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing)."}, {"generated": [], "gold": ["digoxin"], "text": "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection."}, {"generated": [], "gold": ["digoxin"], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": [], "gold": ["digoxin"], "text": "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations."}, {"generated": [], "gold": ["fimasartan"], "text": "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14]."}, {"generated": [], "gold": ["fimasartan-amide", "amlodipine", "Fimasartan", "hydrochlorothiazide"], "text": "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA)."}, {"generated": [], "gold": ["fimasartan-amide", "amlodipine", "Fimasartan", "hydrochlorothiazide"], "text": "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA)."}, {"generated": [], "gold": ["fimasartan-amide", "amlodipine", "Fimasartan", "hydrochlorothiazide"], "text": "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA)."}, {"generated": [], "gold": ["fimasartan-amide", "amlodipine", "Fimasartan", "hydrochlorothiazide"], "text": "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA)."}, {"generated": [], "gold": ["amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": [], "gold": ["amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": [], "gold": ["amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": [], "gold": ["amlodipine"], "text": "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)."}, {"generated": [], "gold": ["fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide."}, {"generated": [], "gold": ["fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide."}, {"generated": [], "gold": ["fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide."}, {"generated": [], "gold": ["fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide."}, {"generated": [], "gold": ["fimasartan"], "text": "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy."}, {"generated": [], "gold": ["amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": [], "gold": ["amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": [], "gold": ["amlodipine", "hydrochlorothiazide", "fimasartan"], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": [], "gold": ["HAART"], "text": "However, there are several challenges associated with the chronic nature of HAART administration."}, {"generated": [], "gold": ["ART"], "text": "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2]."}, {"generated": [], "gold": ["NVP", "EFV"], "text": "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10]."}, {"generated": [], "gold": ["NVP", "EFV"], "text": "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10]."}, {"generated": [], "gold": ["AAP"], "text": "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23]."}, {"generated": [], "gold": ["AAP"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": [], "gold": ["AAP"], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": [], "gold": ["AAP"], "text": "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP."}, {"generated": [], "gold": ["midazolam"], "text": "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance."}, {"generated": [], "gold": ["anticoagulant therapy"], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": [], "gold": ["warfarin"], "text": "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme."}, {"generated": [], "gold": ["quinine", "3-hydroxyquinine"], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": [], "gold": ["quinine", "3-hydroxyquinine"], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": [], "gold": ["quinine"], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": [], "gold": ["quinine sulphate"], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": [], "gold": ["quinine", "quinine sulphate"], "text": "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola."}, {"generated": [], "gold": ["quinine", "quinine sulphate"], "text": "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola."}, {"generated": [], "gold": ["quinine", "3-hydroxyquinine"], "text": "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively."}, {"generated": [], "gold": ["quinine", "3-hydroxyquinine"], "text": "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively."}, {"generated": [], "gold": ["quinine"], "text": "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %."}, {"generated": [], "gold": ["quinine"], "text": "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination."}, {"generated": [], "gold": ["quinine"], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": [], "gold": ["ART"], "text": "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11]."}, {"generated": [], "gold": ["temozolomide"], "text": "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM)."}, {"generated": [], "gold": ["warfarin"], "text": "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser."}, {"generated": [], "gold": ["S-warfarin"], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": [], "gold": ["warfarin", "Warfarin", "S-warfarin", "R-warfarin"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": [], "gold": ["warfarin", "Warfarin", "S-warfarin", "R-warfarin"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": [], "gold": ["warfarin", "Warfarin", "S-warfarin", "R-warfarin"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": [], "gold": ["warfarin", "Warfarin", "S-warfarin", "R-warfarin"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": [], "gold": ["warfarin"], "text": "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3."}, {"generated": [], "gold": ["warfarin", "S-warfarin"], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": [], "gold": ["warfarin", "S-warfarin"], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": [], "gold": ["warfarin"], "text": "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess."}, {"generated": [], "gold": ["warfarin"], "text": "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking."}, {"generated": [], "gold": ["anticancer drugs"], "text": "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs."}, {"generated": [], "gold": ["caffeine", "debrisoquine", "midazolam", "paraxanthine", "chlorzoxazone"], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": [], "gold": ["caffeine", "debrisoquine", "midazolam", "paraxanthine", "chlorzoxazone"], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": [], "gold": ["caffeine", "debrisoquine", "midazolam", "paraxanthine", "chlorzoxazone"], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": [], "gold": ["caffeine", "debrisoquine", "midazolam", "paraxanthine", "chlorzoxazone"], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": [], "gold": ["caffeine", "debrisoquine", "midazolam", "paraxanthine", "chlorzoxazone"], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": [], "gold": ["Haloperidol"], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": [], "gold": ["opioids"], "text": "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible."}, {"generated": [], "gold": ["clarithromycin", "rifampin"], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": [], "gold": ["clarithromycin", "rifampin"], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": [], "gold": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"], "text": "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant."}, {"generated": [], "gold": ["venlafaxine"], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": [], "gold": ["venlafaxine"], "text": "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["antithrombotic drugs", "selective estrogen receptor modulators", "Aspirin", "sleep inducers", "calcitonin", "antihyperlipidemic drugs", "bisphosphonates", "chemotherapy", "Warfarin", "Clopidogrel", "antidepressants"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["valproic acid"], "text": "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25]."}, {"generated": [], "gold": ["valsartan"], "text": "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides."}, {"generated": [], "gold": ["valsartan"], "text": "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8)."}, {"generated": [], "gold": ["valsartan"], "text": "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan."}, {"generated": [], "gold": ["valsartan"], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": [], "gold": ["valsartan"], "text": "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats."}, {"generated": [], "gold": ["CC"], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": [], "gold": ["darunavir-ritonavir", "darunavir"], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": [], "gold": ["darunavir-ritonavir", "darunavir"], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": [], "gold": ["Darunavir"], "text": "Darunavir pharmacokinetics."}, {"generated": [], "gold": ["darunavir"], "text": "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively."}, {"generated": [], "gold": ["darunavir-ritonavir", "ritonavir"], "text": "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea."}, {"generated": [], "gold": ["darunavir-ritonavir", "ritonavir"], "text": "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea."}, {"generated": [], "gold": ["antiretroviral agents"], "text": "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature."}, {"generated": [], "gold": ["darunavir"], "text": "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy."}, {"generated": [], "gold": ["5-OH-OME", "DEX", "DOR", "OME", "MID"], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": [], "gold": ["5-OH-OME", "DEX", "DOR", "OME", "MID"], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": [], "gold": ["5-OH-OME", "DEX", "DOR", "OME", "MID"], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": [], "gold": ["5-OH-OME", "DEX", "DOR", "OME", "MID"], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": [], "gold": ["5-OH-OME", "DEX", "DOR", "OME", "MID"], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": [], "gold": ["warfarin"], "text": "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin."}, {"generated": [], "gold": ["warfarin"], "text": "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin."}, {"generated": [], "gold": ["warfarin"], "text": "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study."}, {"generated": [], "gold": ["warfarin"], "text": "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship."}, {"generated": [], "gold": ["warfarin"], "text": "She had no history of warfarin use, but warfarin was detected in her blood serum analysis."}, {"generated": [], "gold": ["warfarin", "super-warfarin"], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": [], "gold": ["warfarin", "super-warfarin"], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": [], "gold": ["raloxifene"], "text": "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction."}, {"generated": [], "gold": ["raloxifene"], "text": "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential."}, {"generated": [], "gold": ["gliclazide"], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": [], "gold": ["CBZ"], "text": "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7]."}, {"generated": [], "gold": ["CBZ"], "text": "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions."}, {"generated": [], "gold": ["CBZ"], "text": "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365]."}, {"generated": [], "gold": ["folinic acid", "CBZ", "nicotinamide"], "text": "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70]."}, {"generated": [], "gold": ["folinic acid", "CBZ", "nicotinamide"], "text": "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70]."}, {"generated": [], "gold": ["folinic acid", "CBZ", "nicotinamide"], "text": "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70]."}, {"generated": [], "gold": ["antiepileptic therapy"], "text": "Patients on antiepileptic therapy are usually on a long-term basis."}, {"generated": [], "gold": ["CBZ"], "text": "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption."}, {"generated": [], "gold": ["CBZ"], "text": "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder."}, {"generated": [], "gold": ["hypoglycaemic agents"], "text": "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents."}, {"generated": [], "gold": ["aspirin"], "text": "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12]."}, {"generated": [], "gold": ["aspirin"], "text": "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS."}, {"generated": [], "gold": ["omeprazole"], "text": "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B)."}, {"generated": [], "gold": ["rifampicin"], "text": "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17]."}, {"generated": [], "gold": ["cyclosporine A", "rifampicin"], "text": "Results for the positive controls rifampicin and cyclosporine A were published previously [25]."}, {"generated": [], "gold": ["cyclosporine A", "rifampicin"], "text": "Results for the positive controls rifampicin and cyclosporine A were published previously [25]."}, {"generated": [], "gold": ["rifampicin"], "text": "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity."}, {"generated": [], "gold": ["rifampicin"], "text": "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure."}, {"generated": [], "gold": ["bupropion"], "text": "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion."}, {"generated": [], "gold": ["4-hydroxybupropion", "bupropion"], "text": "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion."}, {"generated": [], "gold": ["4-hydroxybupropion", "bupropion"], "text": "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion."}, {"generated": [], "gold": ["bupropion"], "text": "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion."}, {"generated": [], "gold": ["statin", "statins"], "text": "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types."}, {"generated": [], "gold": ["statin", "statins"], "text": "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types."}, {"generated": [], "gold": ["DAS"], "text": "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05)."}, {"generated": [], "gold": ["DAS"], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": [], "gold": ["DAS"], "text": "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact."}, {"generated": [], "gold": ["DAS"], "text": "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O."}, {"generated": [], "gold": ["DAS"], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": [], "gold": ["DAS"], "text": "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings."}, {"generated": [], "gold": ["DAS"], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": [], "gold": ["antidepressant treatment,"], "text": "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test."}, {"generated": [], "gold": ["5-FU"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": [], "gold": ["etoposide", "doxorubicin", "5-FU", "cyclophosphamide", "cisplatin", "carboplatin", "UFT"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": [], "gold": ["etoposide", "doxorubicin", "5-FU", "cyclophosphamide", "cisplatin", "carboplatin", "UFT"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": [], "gold": ["etoposide", "doxorubicin", "5-FU", "cyclophosphamide", "cisplatin", "carboplatin", "UFT"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": [], "gold": ["etoposide", "doxorubicin", "5-FU", "cyclophosphamide", "cisplatin", "carboplatin", "UFT"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": [], "gold": ["etoposide", "doxorubicin", "5-FU", "cyclophosphamide", "cisplatin", "carboplatin", "UFT"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": [], "gold": ["etoposide", "doxorubicin", "5-FU", "cyclophosphamide", "cisplatin", "carboplatin", "UFT"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": [], "gold": ["etoposide", "doxorubicin", "5-FU", "cyclophosphamide", "cisplatin", "carboplatin", "UFT"], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": [], "gold": ["paclitaxel"], "text": "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97]."}, {"generated": [], "gold": ["anticancer drugs"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": [], "gold": ["hormonal therapy"], "text": "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer."}, {"generated": [], "gold": ["dextrorphan-d", "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)"], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": [], "gold": ["dextrorphan-d", "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)"], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": [], "gold": ["endoxifen"], "text": "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig."}, {"generated": [], "gold": ["Dextromethorphan", "Quinidine"], "text": "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM)."}, {"generated": [], "gold": ["Dextromethorphan", "Quinidine"], "text": "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM)."}, {"generated": [], "gold": ["captopril"], "text": "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa."}, {"generated": [], "gold": ["captopril"], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": [], "gold": ["captopril"], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": [], "gold": ["captopril"], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": [], "gold": ["captopril"], "text": "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups."}, {"generated": [], "gold": ["AC"], "text": "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered."}, {"generated": [], "gold": ["SITA"], "text": "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study."}, {"generated": [], "gold": ["Gliptins", "oral anti-diabetic agents"], "text": "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4)."}, {"generated": [], "gold": ["Gliptins", "oral anti-diabetic agents"], "text": "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4)."}, {"generated": [], "gold": ["SITA", "PRM"], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": [], "gold": ["SITA", "PRM"], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": [], "gold": ["\u202fSITA"], "text": "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig."}, {"generated": [], "gold": ["indomethacin"], "text": "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin."}, {"generated": [], "gold": ["indomethacin"], "text": "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study."}, {"generated": [], "gold": ["indomethacin"], "text": "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert."}, {"generated": [], "gold": ["warfarin"], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": [], "gold": ["anticoagulant therapy"], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": [], "gold": ["warfarin"], "text": "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement."}, {"generated": [], "gold": ["warfarin"], "text": "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5]."}, {"generated": [], "gold": ["warfarin"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": [], "gold": ["warfarin"], "text": "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002)."}, {"generated": [], "gold": ["imatinib"], "text": "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance."}, {"generated": [], "gold": ["bosutinib"], "text": "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure."}, {"generated": [], "gold": ["tacrolimus", "midazolam"], "text": "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3."}, {"generated": [], "gold": ["tacrolimus", "midazolam"], "text": "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3."}, {"generated": [], "gold": ["phenytoin", "carbamazepine"], "text": "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction."}, {"generated": [], "gold": ["phenytoin", "carbamazepine"], "text": "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction."}, {"generated": [], "gold": ["antiplatelet agents"], "text": "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents."}, {"generated": [], "gold": ["warfarin"], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": [], "gold": ["warfarin", "diclofenac sodium"], "text": "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA)."}, {"generated": [], "gold": ["warfarin", "diclofenac sodium"], "text": "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA)."}, {"generated": [], "gold": ["warfarin"], "text": "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM."}, {"generated": [], "gold": ["warfarin"], "text": "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32]."}, {"generated": [], "gold": ["warfarin"], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": [], "gold": ["warfarin"], "text": "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54]."}, {"generated": [], "gold": ["warfarin"], "text": "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58]."}, {"generated": [], "gold": ["cyclophosphamide", "phenobarbital"], "text": "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study."}, {"generated": [], "gold": ["cyclophosphamide", "phenobarbital"], "text": "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study."}, {"generated": [], "gold": ["hormone therapy"], "text": "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer."}, {"generated": [], "gold": ["adjuvant chemotherapy"], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": [], "gold": ["placebo"], "text": "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups."}, {"generated": [], "gold": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": [], "gold": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": [], "gold": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": [], "gold": ["simvastatin"], "text": "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin."}, {"generated": [], "gold": ["warfarin"], "text": "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin."}, {"generated": [], "gold": ["warfarin"], "text": "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported."}, {"generated": [], "gold": ["warfarin", "(S)-warfarin"], "text": "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics."}, {"generated": [], "gold": ["warfarin", "(S)-warfarin"], "text": "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics."}, {"generated": [], "gold": ["antihistamines", "glucocorticoids"], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": [], "gold": ["antihistamines", "glucocorticoids"], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": [], "gold": ["OS"], "text": "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas."}, {"generated": [], "gold": ["OSA"], "text": "The formation rate of OSA could be significantly suppressed by all the herb/herbal components."}, {"generated": [], "gold": ["OS"], "text": "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism."}, {"generated": [], "gold": ["OS", "OSA"], "text": "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig."}, {"generated": [], "gold": ["OS", "OSA"], "text": "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig."}, {"generated": [], "gold": ["OS", "OSA"], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": [], "gold": ["OS", "OSA"], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": [], "gold": ["OS"], "text": "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components."}, {"generated": [], "gold": ["OS"], "text": "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components."}, {"generated": [], "gold": ["OS"], "text": "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS."}, {"generated": [], "gold": ["OS"], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": [], "gold": ["TAM"], "text": "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking."}, {"generated": [], "gold": ["TAM"], "text": "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018)."}, {"generated": [], "gold": ["TAM"], "text": "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010)."}, {"generated": [], "gold": ["TAM"], "text": "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012)."}, {"generated": [], "gold": ["TAM"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": [], "gold": ["antibacterial agents"], "text": "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011)."}, {"generated": [], "gold": ["CIP"], "text": "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990)."}, {"generated": [], "gold": ["CIP"], "text": "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012)."}, {"generated": [], "gold": ["CIP"], "text": "The supernate was utilized for the quantification of GA, PCA, and CIP."}, {"generated": [], "gold": ["CIP", "ofloxacin"], "text": "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively."}, {"generated": [], "gold": ["CIP", "ofloxacin"], "text": "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively."}, {"generated": [], "gold": ["CIP"], "text": "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively."}, {"generated": [], "gold": ["CIP", "ciprofloxacin (CIP)"], "text": "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively."}, {"generated": [], "gold": ["CIP", "ciprofloxacin (CIP)"], "text": "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively."}, {"generated": [], "gold": ["CIP", "ciprofloxacin"], "text": "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively."}, {"generated": [], "gold": ["CIP", "ciprofloxacin"], "text": "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively."}, {"generated": [], "gold": ["CIP"], "text": "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia."}, {"generated": [], "gold": ["PLC"], "text": "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3)."}, {"generated": [], "gold": ["isoflurane"], "text": "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane."}, {"generated": [], "gold": ["felodipine"], "text": "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11]."}, {"generated": [], "gold": ["midazolam"], "text": "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88]."}, {"generated": [], "gold": ["bromazepam"], "text": "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104]."}, {"generated": [], "gold": ["midazolam"], "text": "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate."}, {"generated": [], "gold": ["neuropsychiatric drugs"], "text": "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs."}, {"generated": [], "gold": ["calcineurin inhibitors", "Sirolimus"], "text": "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation."}, {"generated": [], "gold": ["calcineurin inhibitors", "Sirolimus"], "text": "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation."}, {"generated": [], "gold": ["sirolimus", "tacrolimus"], "text": "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors."}, {"generated": [], "gold": ["sirolimus", "tacrolimus"], "text": "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors."}, {"generated": [], "gold": ["Sirolimus"], "text": "Sirolimus is an immunosuppressive drug used to prevent graft rejection."}, {"generated": [], "gold": ["sirolimus"], "text": "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins."}, {"generated": [], "gold": ["sirolimus"], "text": "In this patient, we reported the possible effect of parsley juice on the level of sirolimus."}, {"generated": [], "gold": ["sildenafil"], "text": "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil."}, {"generated": [], "gold": ["analgetic drugs"], "text": "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years."}, {"generated": [], "gold": ["opioids"], "text": "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention."}, {"generated": [], "gold": ["anticoagulant or platelet inhibiting co-medication"], "text": "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication."}, {"generated": [], "gold": ["atorvastatin"], "text": "applied atorvastatin in rats after 3 weeks of drinking green tea or water."}, {"generated": [], "gold": ["ASA"], "text": "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234]."}, {"generated": [], "gold": ["ASA", "MTX"], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": [], "gold": ["ASA", "MTX"], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": [], "gold": ["metformin"], "text": "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels."}, {"generated": [], "gold": ["antidiabetics"], "text": "Evidence supporting the interaction between Lycium and antidiabetics is experimental only."}, {"generated": [], "gold": ["antidiabetics"], "text": "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86]."}, {"generated": [], "gold": ["DEX"], "text": "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995)."}, {"generated": [], "gold": ["DEX"], "text": "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996)."}, {"generated": [], "gold": ["betaxolol", "codeine"], "text": "The internal standards codeine and betaxolol were of USP reference standard."}, {"generated": [], "gold": ["betaxolol", "codeine"], "text": "The internal standards codeine and betaxolol were of USP reference standard."}, {"generated": [], "gold": ["DEX"], "text": "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05."}, {"generated": [], "gold": ["DEX"], "text": "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig."}, {"generated": [], "gold": ["abemaciclib"], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}]}